BofA analyst Allen Lutz notes that the Food and Drug Administration yesterday provided updated enforcement timelines for semaglutide and ...

The U.S. Food and Drug Administration said on Monday it will not take action against compounding pharmacies making copies of ...

In today’s evolving pharmaceutical environment, the fill‐finish segment stands out as a critical linchpin connecting drug ...

A federal judge has shut down compounding pharmacies from making cheaper versions of Eli Lilly’s weight loss and diabetes ...

Compounders had been allowed to produce and sell hundreds of thousands of their own versions of popular anti-obesity drugs, so long as the FDA considered them in shortage.

A federal judge ended compounding pharmacies’ ability to make copies of the weight loss and diabetes drugs Zepbound and ...

On February 21, 2025, the US Food and Drug Administration (FDA) revised its shortage categorization of semaglutide, a glucagon-like peptide 1 ...

Compounders had been allowed to produce and sell hundreds of thousands of their own versions of popular anti-obesity drugs.

A U.S. federal judge has restricted compounding pharmacies from making copies of Eli Lilly's weight-loss and diabetes drugs due to a lawsuit against the FDA's decision that there's no longer a ...

In today’s fast-paced business environment, workplace productivity has become more important than ever. Companies are ...

The last few years have seen several major disruptions that have impacted businesses and operations. Events like the COVID-19 ...